Eisai's eritoran revived as COVID-19 hopeful

1 July 2020

2019_vial_production_biotech_manufacturing_big

A TLR-4 antagonist has been selected as the first investigational immune modulation therapy to be included in the “moderate” arm of an adaptive trial testing therapies against COVID-19.

Eritoran, an investigational TLR-4 antagonist discovered and developed by Japanese drug major Eisai (TYO: 4523), will be included in the REMAP-COVID study, led by the Los Angeles-based non-profit Global Coalition for Adaptive Research (GCAR).

Eisai was previously developing the candidate for the treatment of severe sepsis, but late-stage failures in 2011 and 2013 put paid to the program.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK